Table 1 Patient demographics of stage IV NSCLC cohort

Age (years), median (range)

61 (33–90)

64 (39–78)

WBC count (e⁶), median (range)

6.8 (0.8–29.9)

8.1 (3.5–19.9)

Sex, n (%)

 Female

37 (45.7)

11 (44.0)

 Male

32 (39.5)

13 (52.0)

 N/A

12 (14.8)

1 (4.0)

Histologll, n (%)

 ACA

66 (81.5)

20 (80.0)

 Sec

8 (9.9)

4 (16.0)

 LCC

1 (1.2)

–

 NOS

3 (3.7)

1 (4.0)

 N/A

3 (3.7)

–

Location of primary mass, n (%)

 RUL

26 (32.1)

7 (28.0)

 LUL

22 (27.2)

8 (30.0)

 RML

3 (3.7)

–

 RLL

13 (16.0)

3 (12.0)

 LLL

12 (14.8)

2 (8.0)

 R Hilum

1 (1.2)

1 (4.0)

 None

2 (2.5)

1 (4.0)

 N/A

2 (2.5)

3 (12.0)

Stage, n (%)

 IVA

18 (22.2)

6 (24.0)

 IVB

40 (49.4)

18 (72.0)

Recurrent metastatic

1 (4.0)

 IVA

5 (6.2)

–

 IVB

13 (16.0)

–

 N/A

5 (6.2)

–

Therpay, n (%)

 Entering 1st line

75 (92.6)

24 (96.0)

  Crizotinib

1 (1.2)

1 (4.0)

  Erlotinib

9 (11.1)

2 (8.0)

  Platinum2

35 (43.2)

14 (56.0)

  Platinum2 + erlotinib

1 (1.2)

–

  Platinum3

28 (34.6)

7 (28.0)

  Pemetrexed

1 (1.2)

–

 Entering 2nd line

48 (59.3)

12 (48.0)

  Crizotinib

2 (2.5)

1 (4.0)

  Docetaxel

1 (1.2)

–

  Erlotinib

37 (45.7)

8 (32.0)

  Navelbine

1 (1.2)

–

  Platinum2

3 (3.7)

2 (8.0)

  Platinum3

3 (3.7)

1 (4.0)

  Taxotere

1 (1.2)

–

 Entering 3rd line

21 (25.9)

5 (20.0)

  Crizotinib

1 (1.2)

–

  Docetaxel

1 (1.2)

–

  Erlotinib

10 (12.3)

4 (16.0)

  Gemcitabine

1 (1.2)

–

  Navelbine

1 (1.2)

–

  Platinum2

5 (6.2)

1 (4.0)

  Platinum3

1 (1.2)

–

  Pemetrexed

1 (1.2)

–

 Entering 4th line

18 (22.2)

2 (8.0)

  Crizotinib

1 (1.2)

–

  Erlotinib

4 (4.9)

1 (4.0)

  Navelbine

10 (12.3)

1 (4.0)

  Platinum2

2 (2.5)

–

  Other

1 (1.2)

–

 Entering 5th line

5 (6.2)

–

  Navelbine

4 (4.9)

–

  Platinum2

1 (1.2)

–

 Entering 6th line

–

–

  Erlotinib

2 (2.5)

–

 Entering 7th line

–

–

  Navelbine

1 (1.2)

–

 Entering 8th line

–

–

  Etoposide

1 (1.2)

–

Site of secondary metastatic lesions, n (%)

 Adrenal gland

8 (9.9)

4 (16.0)

 Bone

32 (39.5)

10 (40.0)

 Brain

21 (25.9)

6 (24.0)

 Liver

14 (17.3)

3 (12.0)

 Pleura

29 (35.8)

6 (24.0)

 Lung

28 (34.6)

8 (32.0)

 Kidney

1 (1.2)

–

 Pericardium

3 (3.7)

–

 Muscle

1 (1.2)

1 (4.0)

 Skin

2 (2.5)

1 (4.0)

 Axillary LN

3 (3.7)

–

 Spleen

1 (1.2)

–

Number of distant metastatic lesions, n (%)

 0

23 (28.4)

8 (32.0)

 1

37 (45.7)

11 (44.0)

 2

19 (23.5)

3 (12.0)

 3

20 (2.5)

3 (12.0)

Mutation, n(%)

 ALK

  Positive

2 (2.5)

1 (4.0)

  Negative

3 (3.7)

2 (8.0)

 KRAS

  WT

12 (14.8)

3 (12.0)

  Mutant

6 (7.4)

4 (16.0)

 EGFR

  WT

10 (12.3)

–

  Mutant

7 (8.6)

–